rts logo

Akebia Therapeutics Inc. (AKBA) Stock Could Soon Reward Patient Investors

Akebia Therapeutics Inc. (NASDAQ: AKBA) is 27.42% higher on its value in year-to-date trading and has touched a low of $0.49 and a high of $2.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKBA stock was last observed hovering at around $1.63 in the last trading session, with the day’s loss setting it -0.05%.

Currently trading at $1.58, the stock is -9.09% and -2.98% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 8.07 million and changing -3.07% at the moment leaves the stock 23.11% off its SMA200. AKBA registered 180.54% gain for a year compared to 6-month gain of 38.60%. The firm has a 50-day simple moving average (SMA 50) of $1.73 and a 200-day simple moving average (SMA200) of -$83.03.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a -7.60% loss in the last 1 month and extending the period to 3 months gives it a 27.42%, and is -28.51% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 20.92% over the week and 12.43% over the month.

Akebia Therapeutics Inc. (AKBA) has around 167 employees, a market worth around $330.80M and $194.75M in sales. Profit margin for the company is -26.32%. Distance from 52-week low is 222.38% and -36.29% from its 52-week high. The company has generated returns on investments over the last 12 months (-103.44%).

Akebia Therapeutics Inc. quarterly earnings per share for the current quarter are estimated at -$0.08 with sales reaching $46.34M over the same period.The EPS is expected to grow by 0.32% this year, but quarterly earnings will post -2.80% year-over-year. Quarterly sales are estimated to grow 15.50% in year-over-year returns.

Akebia Therapeutics Inc. (AKBA) Top Institutional Holders

100 institutions hold shares in Akebia Therapeutics Inc. (AKBA), with institutional investors hold 26.98% of the company’s shares. The shares outstanding are 194.58M, and float is at 184.15M with Short Float at 5.50%. Institutions hold 26.28% of the Float.

The top institutional shareholder in the company is Alerce Investment Management, L.P. with over 16.21 million shares valued at $14.83 million. The investor’s holdings represent 8.61% of the AKBA Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 7.81 million shares valued at $7.15 million to account for 4.15% of the shares outstanding. The other top investors are Acadian Asset Management. LLC which holds 7.46 million shares representing 3.96% and valued at over $6.83 million, while Renaissance Technologies, LLC holds 1.77% of the shares totaling 3.33 million with a market value of $3.05 million.

Akebia Therapeutics Inc. (AKBA) Insider Activity

The most recent transaction is an insider sale by Butler John P.,the company’sCEO and President. SEC filings show that Butler John P. sold 46,570 shares of the company’s common stock on Feb 29 ’24 at a price of $1.58 per share for a total of $73581.0. Following the sale, the insider now owns 2.04 million shares.

Akebia Therapeutics Inc. disclosed in a document filed with the SEC on Feb 29 ’24 that Dahan Michel (SVP, Chief Operating Officer) sold a total of 8,661 shares of the company’s common stock. The trade occurred on Feb 29 ’24 and was made at $1.58 per share for $13684.0. Following the transaction, the insider now directly holds 0.71 million shares of the AKBA stock.

Still, SEC filings show that on Feb 29 ’24, Burke Steven Keith (SVP, Chief Medical Officer) disposed off 7,169 shares at an average price of $1.58 for $11327.0. The insider now directly holds 695,840 shares of Akebia Therapeutics Inc. (AKBA).

Related Posts